Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
An article from
Dive Brief
//
China competition
Set to go public via a reverse merger, Avere has licensed from a prolific Chinese drugmaker rights to a potential threat to medicines like Skyrizi and Icotyde.
Merging with NextCure, Avere Therapeutics is based on a clinical-stage oral IL-23 receptor antagonist licensed from China's…
A therapy that works similarly to AbbVie’s blockbuster Skyrizi appeared more potent in a mid-stage trial and has the potential to…
Since they were approved four months apart in 2019, AbbVie’s Skyrizi and Rinvoq have been joined at the hip, central to the…
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001
FDA approves AbbVie Skyrizi for pediatric psoriasis, while EU’s CHMP backs Rinvoq for vitiligo and alopecia. Read the latest…
Avenzo Therapeutics, one of the first biotechs to get major Western VC backing to in-license Chinese assets, will go public in a…
After $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drug
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
Akero team, backed by Fairmount, launches new immunology company
